Credit Suisse’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-131,712
| Closed | -$8.97M | – | 4250 |
|
|
2022
Q3 | $8.97M | Buy |
131,712
+78,996
| +150% | +$4.36M | 0.01% | 968 |
|
|
2022
Q2 | $1.68M | Sell |
52,716
-5,706
| -10% | -$167K | ﹤0.01% | 2036 |
|
|
2022
Q1 | $2.02M | Buy |
58,422
+3,989
| +7% | +$119K | ﹤0.01% | 2069 |
|
|
2021
Q4 | $1.59M | Sell |
54,433
-2,014
| -4% | -$62.4K | ﹤0.01% | 2962 |
|
|
2021
Q3 | $1.44M | Buy |
56,447
+3,076
| +6% | +$90.4K | ﹤0.01% | 3062 |
|
|
2021
Q2 | $1.87M | Sell |
53,371
-11,089
| -17% | -$433K | ﹤0.01% | 2919 |
|
|
2021
Q1 | $2.63M | Sell |
64,460
-22,602
| -26% | -$1.04M | ﹤0.01% | 2609 |
|
|
2020
Q4 | $3.77M | Buy |
87,062
+815
| +0.9% | +$40.2K | ﹤0.01% | 2331 |
|
|
2020
Q3 | $4.76M | Buy |
86,247
+2,845
| +3% | +$181K | ﹤0.01% | 1818 |
|
|
2020
Q2 | $5.27M | Buy |
83,402
+25,784
| +45% | +$1.77M | ﹤0.01% | 1676 |
|
|
2020
Q1 | $2.94M | Sell |
57,618
-25,364
| -31% | -$1.7M | ﹤0.01% | 1862 |
|
|
2019
Q4 | $6.6M | Buy |
82,982
+38,258
| +86% | +$2.27M | ﹤0.01% | 1692 |
|
|
2019
Q3 | $2.17M | Sell |
44,724
-157,013
| -78% | -$8.18M | ﹤0.01% | 2409 |
|
|
2019
Q2 | $10.6M | Buy |
201,737
+164,987
| +449% | +$9.48M | 0.01% | 1280 |
|
|
2019
Q1 | $1.94M | Sell |
36,750
-137
| -0.4% | -$6.73K | ﹤0.01% | 2394 |
|
|
2018
Q4 | $1.51M | Sell |
36,887
-10,422
| -22% | -$391K | ﹤0.01% | 2454 |
|
|
2018
Q3 | $1.8M | Sell |
47,309
-4,861
| -9% | -$215K | ﹤0.01% | 2428 |
|
|
2018
Q2 | $2.36M | Sell |
52,170
-4,541
| -8% | -$207K | ﹤0.01% | 2322 |
|
|
2018
Q1 | $2.74M | Buy |
56,711
+20,113
| +55% | +$1.12M | ﹤0.01% | 2163 |
|
|
2017
Q4 | $1.44M | Sell |
36,598
-77,647
| -68% | -$2.9M | ﹤0.01% | 2721 |
|
|
2017
Q3 | $3.55M | Buy |
114,245
+4,549
| +4% | +$128K | ﹤0.01% | 2054 |
|
|
2017
Q2 | $3M | Buy |
109,696
+18,581
| +20% | +$553K | ﹤0.01% | 1961 |
|
|
2017
Q1 | $3.36M | Sell |
91,115
-2,461
| -3% | -$62K | ﹤0.01% | 1945 |
|
|
2016
Q4 | $1.35M | Buy |
93,576
+77,159
| +470% | +$1.36M | ﹤0.01% | 2778 |
|
|
2016
Q3 | $379K | Sell |
16,417
-14,922
| -48% | -$284K | ﹤0.01% | 3557 |
|
|
2016
Q2 | $519K | Buy |
31,339
+12,968
| +71% | +$262K | ﹤0.01% | 3404 |
|
|
2016
Q1 | $291K | Buy |
18,371
+11,700
| +175% | +$208K | ﹤0.01% | 3525 |
|
|
2015
Q4 | $215K | Sell |
6,671
-8,300
| -55% | -$359K | ﹤0.01% | 3850 |
|
|
2015
Q3 | $631K | Buy |
+14,971
| New | +$706K | ﹤0.01% | 3224 |
|
Other funds holding GBT
Credit Suisse's GBT Position: Q4 2022 in Review
Credit Suisse sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 131,712 shares — an estimated $8.97M sold.
Credit Suisse first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $10.6M in Q2 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Credit Suisse reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Credit Suisse sold 131,712 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.97M.
- Credit Suisse first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Credit Suisse's Global Blood Therapeutics, Inc. position peaked at $10.6M in Q2 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.